The endocannabinoid system modulates learning, memory,
and neuroinflammatory
processes, playing a key role in neurodegeneration, including Alzheimer’s
disease (AD). Previous results in a rat lesion model of AD showed
modulation of endocannabinoid receptor activity in the basalo-cortical
pathway following a specific lesion of basal forebrain cholinergic
neurons (BFCNs), indicating that the glial neuroinflammatory response
accompanying the lesion is related to endocannabinoid signaling. In
this study, 7 days after the lesion, decreased astrocyte and increased
microglia immunoreactivities (GFAP and Iba-1) were observed, indicating
microglia-mediated neuroinflammation. Using autoradiographic studies,
the density and functional coupling to G-proteins of endocannabinoid
receptor subtypes were studied in tissue sections from different brain
areas where microglia density increased, using CB1 and
CB2 selective agonists and antagonists. In the presence
of the specific CB1 receptor antagonist, SR141716A, [3H]CP55,940 binding (receptor density) was completely blocked
in a dose-dependent manner, while the selective CB2 receptor
antagonist, SR144528, inhibited binding to 25%, at best. [35S]GTPγS autoradiography (receptor coupling to Gi/0-proteins) evoked by CP55,940 (CB1/CB2 agonist)
and HU308 (more selective for CB2) was abolished by SR141716A
in all areas, while SR144528 blocked up to 51.8% of the coupling to
Gi/0-proteins evoked by CP55,940 restricted to the nucleus
basalis magnocellularis. Together, these results demonstrate that
there are increased microglia and decreased astrocyte immunoreactivities
1 week after a specific deletion of BFCNs, which projects to cortical
areas, where the CB1 receptor coupling to Gi/0-proteins is upregulated. However, at the lesion site, the area with
the highest neuroinflammatory response, there is also a limited contribution
of CB2.